
Cardiol Therapeutics (CRDL) Stock Forecast & Price Target
Cardiol Therapeutics (CRDL) Analyst Ratings
Bulls say
Cardiol Therapeutics is a promising late-stage life sciences company with a focus on developing innovative therapies for heart disease. The company's primary small-molecule candidate, CardiolRx, has shown promising results in suppressing disease activity in clinical studies, with a low recurrence rate after withdrawal. The company's plans for expanding enrollment in its MAVERIC trial and the encouraging read-through from other withdrawal trials suggest a potential for long-term success and a strong outlook for the company's stock.
Bears say
Cardiol Therapeutics is developing anti-inflammatory and anti-fibrotic therapies for heart disease, but with a negative outlook. The MAVERIC studies have shown a lower-than-expected recurrence rate, but the company has increased the enrollment criteria to potentially mitigate the risk. Peer-reviewed Phase II data have provided support for the potential of CardiolRx as an oral treatment for recurrent pericarditis, but the market continues to underappreciate its potential. However, we believe the ongoing MAVERIC trial and published data strengthen the clinical rationale and present a favorable risk-reward for the company.
This aggregate rating is based on analysts' research of Cardiol Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Cardiol Therapeutics (CRDL) Analyst Forecast & Price Prediction
Start investing in Cardiol Therapeutics (CRDL)
Order type
Buy in
Order amount
Est. shares
0 shares